Epizyme, Inc. (NASDAQ:EPZM) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Saturday, August 5th.
EPZM has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating and issued a $25.00 price objective on shares of Epizyme in a research note on Wednesday, June 7th. Royal Bank Of Canada set a $20.00 price objective on Epizyme and gave the stock a “buy” rating in a research note on Monday, June 12th. Zacks Investment Research raised Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price objective on the stock in a research note on Tuesday, May 16th. Cann reissued an “outperform” rating and issued a $26.00 price objective on shares of Epizyme in a research note on Wednesday, April 12th. Finally, Wedbush reissued an “outperform” rating and issued a $24.00 price objective on shares of Epizyme in a research note on Thursday, May 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $23.38.
Epizyme (NASDAQ EPZM) opened at 14.10 on Friday. The firm’s 50-day moving average is $13.68 and its 200 day moving average is $14.48. Epizyme has a one year low of $7.02 and a one year high of $18.50. The company’s market capitalization is $824.37 million.
Epizyme (NASDAQ:EPZM) last announced its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.08. Epizyme had a negative return on equity of 63.10% and a negative net margin of 1,376.33%. The firm had revenue of $10 million for the quarter, compared to the consensus estimate of $3.95 million. During the same quarter in the previous year, the business earned ($0.49) EPS. The firm’s revenue for the quarter was up 2027.7% on a year-over-year basis. On average, equities analysts expect that Epizyme will post ($2.39) EPS for the current fiscal year.
In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $16.11, for a total value of $241,650.00. Following the transaction, the insider now owns 22,228 shares in the company, valued at $358,093.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew E. Singer sold 3,024 shares of the business’s stock in a transaction dated Friday, June 30th. The shares were sold at an average price of $15.50, for a total value of $46,872.00. Following the completion of the transaction, the chief financial officer now owns 40,529 shares in the company, valued at approximately $628,199.50. The disclosure for this sale can be found here. Insiders have sold 50,524 shares of company stock worth $746,797 in the last quarter. 25.20% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. purchased a new position in shares of Epizyme during the fourth quarter worth approximately $351,000. State Street Corp boosted its stake in shares of Epizyme by 49.4% in the fourth quarter. State Street Corp now owns 1,088,635 shares of the biopharmaceutical company’s stock worth $13,173,000 after buying an additional 359,859 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in shares of Epizyme by 11.9% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,680 shares of the biopharmaceutical company’s stock worth $371,000 after buying an additional 3,269 shares in the last quarter. Norges Bank bought a new stake in shares of Epizyme during the fourth quarter worth $5,961,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Epizyme by 8.2% in the first quarter. Bank of New York Mellon Corp now owns 196,837 shares of the biopharmaceutical company’s stock worth $3,377,000 after buying an additional 14,978 shares in the last quarter. Hedge funds and other institutional investors own 81.24% of the company’s stock.
About Epizyme
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
